BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 15616615)

  • 1. The real gordian knot: racemic mixtures versus pure enantiomers.
    Szelenyi I; Geisslinger G; Polymeropoulos E; Paul W; Herbst M; Brune K
    Drug News Perspect; 1998 Apr; 11(3):139-60. PubMed ID: 15616615
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Chiral switch: pure enantiomers of drugs instead of racemic mixtures].
    Valentová J; Hutt AJ
    Ceska Slov Farm; 2004 Nov; 53(6):285-93. PubMed ID: 15630994
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chiral Switch Drugs for Asthma and Allergies: True Benefit or Marketing Hype.
    Blake K; Raissy H
    Pediatr Allergy Immunol Pulmonol; 2013 Sep; 26(3):157-160. PubMed ID: 24066264
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The development of single-isomer molecules: why and how.
    Hutt AJ
    CNS Spectr; 2002 Apr; 7(4 Suppl 1):14-22. PubMed ID: 15131488
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chiral Aspects of Local Anesthetics.
    Čižmáriková R; Čižmárik J; Valentová J; Habala L; Markuliak M
    Molecules; 2020 Jun; 25(12):. PubMed ID: 32545678
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Chiral switch: towards a better benefit-risk ratio?].
    Blin O
    Therapie; 2004; 59(6):625-8. PubMed ID: 15789826
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chirality and pharmacokinetics: an area of neglected dimensionality?
    Hutt AJ
    Drug Metabol Drug Interact; 2007; 22(2-3):79-112. PubMed ID: 17708062
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bioequivalence of chiral drugs. Stereospecific versus non-stereospecific methods.
    Mehvar R; Jamali F
    Clin Pharmacokinet; 1997 Aug; 33(2):122-41. PubMed ID: 9260035
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chiral Switch: Between Therapeutical Benefit and Marketing Strategy.
    Hancu G; Modroiu A
    Pharmaceuticals (Basel); 2022 Feb; 15(2):. PubMed ID: 35215352
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug disposition in three dimensions: an update on stereoselectivity in pharmacokinetics.
    Brocks DR
    Biopharm Drug Dispos; 2006 Nov; 27(8):387-406. PubMed ID: 16944450
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Racemic therapeutics--ethical and regulatory aspects.
    Ariëns EJ
    Eur J Clin Pharmacol; 1991; 41(2):89-93. PubMed ID: 1743252
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exploration of the impact of stereochemistry on the identification of the novel translocator protein PET imaging agent [(18)F]GE-180.
    Chau WF; Black AM; Clarke A; Durrant C; Gausemel I; Khan I; Mantzilas D; Oulie I; Rogstad A; Trigg W; Jones PA
    Nucl Med Biol; 2015 Sep; 42(9):711-9. PubMed ID: 26072270
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bioequivalence of racemic drugs.
    Nerurkar SG; Dighe SV; Williams RL
    J Clin Pharmacol; 1992 Oct; 32(10):935-43. PubMed ID: 1447402
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Understanding chirality and stereochemistry: three-dimensional psychopharmacology.
    Howland RH
    J Psychosoc Nurs Ment Health Serv; 2009 Jul; 47(7):15-8. PubMed ID: 19678474
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Racemic mixtures: harmless or potentially toxic?
    Ehrlich GE
    Am J Hosp Pharm; 1992 Sep; 49(9 Suppl 1):S15-8. PubMed ID: 1530003
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single-isomer science: the phenomenon and its terminology.
    Gal J
    CNS Spectr; 2002 Apr; 7(4 Suppl 1):8-13. PubMed ID: 15131487
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chirality and nonsteroidal anti-inflammatory drugs.
    Hayball PJ
    Drugs; 1996; 52 Suppl 5():47-58. PubMed ID: 8922556
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent advances in chirally pure proton pump inhibitors.
    Pai V; Pai N
    J Indian Med Assoc; 2007 Aug; 105(8):469-70, 472, 474. PubMed ID: 18236913
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stereoisomeric separation and bioassay of a new organophosphorus compound, O,S-dimethyl-N-(2,2,2-trichloro-1-methoxyethyl)phosphoramidothioate: some implications for chiral switch.
    Zhou S; Wang L; Li L; Liu W
    J Agric Food Chem; 2009 Aug; 57(15):6920-6. PubMed ID: 19603750
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The cost benefit ratio of enantiomeric drugs.
    Pifferi G; Perucca E
    Eur J Drug Metab Pharmacokinet; 1995; 20(1):15-25. PubMed ID: 7588989
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.